Skip to content

A randomized controlled trial of TDCS that improves cognitive function in patients with schizophrenia

A randomized controlled trial of TDCS that improves cognitive function in patients with schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077443
Enrollment
Unknown
Registered
2023-11-08
Start date
2023-09-20
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

stimulate group:The experimental group gave the second generation antipsychotic drugs based on sham stimulation twice a day of 2mA 20min starstimTDCS for transcranial direct current stimulation
sham group:False stimulation was given on the basis of the second-generation antipsychotics, and the stimulation intensity was consistent in site and stimulation time. At 2mA 20min twice daily for 5 c
Drug group:Second-generation antipsychotics

Sponsors

Third People's Hospital of Lanzhou City/ Gansu University Of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: The hospitalized patients from September 2023 to May 2024, who met the DSM-5 diagnostic criteria for schizophrenia, were hospitalized and receiving antipsychotic treatment for> 2 weeks, with PANSS score (60-120), (2) age 18-55 years old, male and female; (3) right-handed; (4) can cooperate with medical staff and sign informed consent. (5) cultural level of primary school or above. MoCA <26, (with MoCA (cognitive difficulties in screening subjects)

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) comorbidities meet ICD-10 other than schizophrenia, such as obsessive-compulsive disorder, phobia, anxiety disorder, depression, panic disorder or stress-related disorder; (2) clinical diagnosis of organic brain lesions: epilepsy, stroke, Alzheimer's disease, Parkinson's disease and other neurological diseases; medical (diabetes, hypothyroidism, myocardial infarction, etc.) with heart disease, pregnancy risk, cardiac pacemaker or any metal implant.(3) modified electroconvulsive therapy (modified electra convulsive therapy, MECT) within 1 month before evaluation.

Design outcomes

Primary

MeasureTime frame
MoCA score;;B-CATSscore;SSPIscore;

Secondary

MeasureTime frame
PANSSscore;

Countries

China

Contacts

Public ContactLi Yaju/ huo xiao ning

Gansu University Of Chinese Medicine/ Third People's Hospital of Lanzhou City

m17352103606@163.com+86 173 5210 3606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026